ENDRA Life Sciences Statistics
Share Statistics
ENDRA Life Sciences has 536.91K shares outstanding. The number of shares has increased by 114.55% in one year.
| Shares Outstanding | 536.91K |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -74.19% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 536.81K |
| Failed to Deliver (FTD) Shares | 3.09K |
| FTD / Avg. Volume | 1.15% |
Short Selling Information
The latest short interest is 24.03K, so 4.48% of the outstanding shares have been sold short.
| Short Interest | 24.03K |
| Short % of Shares Out | 4.48% |
| Short % of Float | 4.48% |
| Short Ratio (days to cover) | 0.05 |
Valuation Ratios
The PE ratio is -3332.68 and the forward PE ratio is -0.02.
| PE Ratio | -3332.68 |
| Forward PE | -0.02 |
| PS Ratio | 0 |
| Forward PS | 7.6 |
| PB Ratio | 5924.65 |
| P/FCF Ratio | -3498.77 |
| PEG Ratio | n/a |
Enterprise Valuation
ENDRA Life Sciences Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.36, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.36 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.5 |
| Cash Flow / Debt | -335.23 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.78% and return on capital (ROIC) is -173.8%.
| Return on Equity (ROE) | -1.78% |
| Return on Assets (ROA) | -1.49% |
| Return on Capital (ROIC) | -173.8% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -479.06K |
| Employee Count | 21 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -99.83% in the last 52 weeks. The beta is 0.74, so ENDRA Life Sciences 's price volatility has been higher than the market average.
| Beta | 0.74 |
| 52-Week Price Change | -99.83% |
| 50-Day Moving Average | 6.96 |
| 200-Day Moving Average | 351.56 |
| Relative Strength Index (RSI) | 35.66 |
| Average Volume (20 Days) | 269.59K |
Income Statement
In the last 12 months, ENDRA Life Sciences had revenue of $0 and earned -$10.06M in profits. Earnings per share was $-1.11.
| Revenue | 0 |
| Gross Profit | -275.45K |
| Operating Income | -10.52M |
| Net Income | -10.06M |
| EBITDA | -9.78M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.11 |
Balance Sheet
The company has $2.83M in cash and $394.40K in debt, giving a net cash position of $2.44M.
| Cash & Cash Equivalents | 2.83M |
| Total Debt | 394.40K |
| Net Cash | 2.44M |
| Retained Earnings | -91.93M |
| Total Assets | 8.38M |
| Working Capital | 4.15M |
Cash Flow
In the last 12 months, operating cash flow was -$9.55M and capital expenditures -$33.88K, giving a free cash flow of -$9.58M.
| Operating Cash Flow | -9.55M |
| Capital Expenditures | -33.88K |
| Free Cash Flow | -9.58M |
| FCF Per Share | -1.06 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NDRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -26.18% |
| FCF Yield | -420.94% |
Analyst Forecast
The average price target for NDRA is $14000, which is 330088.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $14000 |
| Price Target Difference | 330088.7% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 7, 2024. It was a backward split with a ratio of 1:35.
| Last Split Date | Nov 7, 2024 |
| Split Type | backward |
| Split Ratio | 1:35 |
Scores
| Altman Z-Score | -18.29 |
| Piotroski F-Score | 5 |